Clearstead Advisors’s Tenaya Therapeutics TNYA Stock Holding History

Clearstead Advisors’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-82	Closed	-$51	–	3247
2025 Q2	$51	Buy	+82	New	+$42	﹤0.01%	2666

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Clearstead Advisors's TNYA Position: Q3 2025 in Review

Clearstead Advisors sold out of Tenaya Therapeutics (TNYA) in Q3 2025, closing a stake of 82 shares — an estimated $51 sold.

Clearstead Advisors first reported a position in TNYA in Q2 2025 and held it in 1 quarter. The position peaked at $51 in Q2 2025. 91 funds tracked by Wall St. Rank hold TNYA as of Q3 2025.

Clearstead Advisors reported no remaining Tenaya Therapeutics position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 82 Tenaya Therapeutics shares in Q3 2025, an estimated $51.
Clearstead Advisors first reported a position in Tenaya Therapeutics in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Tenaya Therapeutics position peaked at $51 in Q2 2025.
91 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.